Open AccessP757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT‐NAIVE AND RELAPSED HIGH‐RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA
Author(s) -
Bazinet A.,
Jabbour E.,
Kantarjian H.,
Chien K.,
DiNardo C.,
Ohanian M.,
Daver N.,
KanagalShamanna R.,
Kadia T.,
Takahashi K.,
Masarova L.,
Short N.,
Alvarado Y.,
Thompson P.,
MontalbanBravo G.,
Yilmaz M.,
Ravandi F.,
Konopleva M.,
Andreeff M.,
Kornblau S.,
Pemmaraju N.,
Hammond D.,
Schneider H.,
Mirabella B.,
GarciaManero G.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845912.50259.67
Subject(s) - medicine , decitabine , tolerability , azacitidine , international prognostic scoring system , myelodysplastic syndromes , ven , neutropenia , oncology , lenalidomide , venetoclax , chronic myelomonocytic leukemia , adverse effect , hypomethylating agent , leukemia , bone marrow , chronic lymphocytic leukemia , chemotherapy , multiple myeloma , biochemistry , gene expression , chemistry , computer security , computer science , dna methylation , gene